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1. Introduction 
1.1 An era before antibiotic treatments 
Modern pharmaceutical advancements have placed us in an era where fatalities due to 
common communicable diseases such as pneumonia or plague are rare. It is difficult to 
imagine a time when antibiotics were not used as the "fix all" for common illnesses, and even 
used in cases where antibiotic treatment is not indicated. Although we generally take current 
treatments for granted, it is important to point out that historically speaking, available 
treatments for bacterial illnesses were not developed until nearly one-third of the way through 
the 20th century. It is the accidental discovery of penicillin in 1928 by Alexander Fleming that is 
considered perhaps one of the largest medical advancements of modern medicine (Bellis, n.d). 
Prior to the discovery and subsequent development of penicillin, epidemics and pandemics 
were more frequent, more prominent, and carried larger death tolls.  
Early records identify epidemics of plague in Egypt as early as 1650BC, although it is not 
clear whether it was plague or influenza (Austin, 2003; Daileader, 2007; Wade, 2010). The 
first major plague outbreak, which is now considered the beginning of the first plague 
pandemic, began in the Byzantine Empire around 541. The "Black Death" which affected 
Europe and Asia from 1338 to 1351 claiming 100,000,000 lives marks the beginning of the 
second plague pandemic and carries the largest death toll to date. The "Black Death" plague 
re-occurred in several smaller outbreaks including the 1665 "Great Plague of London" as 
well as outbreaks in France, Spain, and Vienna. The third plague pandemic began in 1873 in 
China and eventually spread to India, South Africa, North America, South America, and 
Australia. The death toll in Hong Kong and India from this pandemic breached 12,500,000 
before 1957 (Williams, 1997).  
 
Plague Pandemic Death Toll Location 
1st Pandemic (Byzantine Plague) c541-c639 ~25,000,000 Southern Europe 
2nd Pandemic 1338-1665 (Black Death, 1338-1351) >100,000,000* N. Europe, Asia 
3rd Pandemic 1873-1957 >12,500,000 
Europe, N. Asia, India, 
China 
Table 1. Comparison of death toll and location for historical plague pandemics (Austin, 
2003; Daileader, 2007; Wade, 2010; Williams, 1997). *Death toll from black death period only.  
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As mortality trends are examined prior to the development of penicillin, it is easy to observe 
the effect that penicillin had on survival rates. Although we see a substantial number of 
fatalities, predominately in India, related to the third pandemic of plague, it is important to 
observe not only the difference in population at the time, but also length of time that 
continued outbreaks occurred. For example, it is roughly estimated that 75-200 million 
people were lost during the 14th century outbreaks, with a large geographical range 
including Northern European climates (England and France) in addition to Southern 
European regions such as Italy and Southern Spain. Recent studies suggest that this 
represented approximately 20% of the population in Northern European regions, and a 
striking 75-80% of the population in Europe's Southern countries (Daileader, 2007). The 
most recent plague pandemic started roughly in 1873 in China and spread throughout India, 
the Americas, South Africa and Australia claiming more than 12.5 million (in China and 
India alone) before the late 1950s. This particular pandemic encompassed a larger 
geographical region, albeit during a time of more expedited travel. Although the death toll 
associated with this plague pandemic is large, the plague of the 14th century claimed at least 
six times more individuals during a time when there were fewer people. Hong Kong 
experienced a prolonged and repeated outbreak for a few years which claimed 
approximately 90% of their population (an estimated 8600 total losses) (Pryor, 1975). Despite 
these isolated large death rates, the actual count of lives lost throughout the eight decades 
included in this most recent pandemic is extremely low when compared to those from the 
Black Death.  
One might assume that the discovery and subsequent mass production of penicillin is 
related to this decrease in fatalities. Although the development of penicillin as well as 
other antibiotics or alternative treatments likely played a substantial role in ultimately 
stopping the pandemic, it is most definitely not that simple. Generally speaking, the 
following major differences existed this time around as compared to the first and second 
pandemics: 1) Penicillin was mass produced and readily available near the end of the 
third pandemic. 2) Increased travel opportunity and trade lines contributed to the 
increase in affected regions. 3) Scientific studies have suggested that this plague was not 
as contagious. 4) There were considerably larger populations during this pandemic. 5) 
Population density in the regions with highest fatality were high. 6) This pandemic 
(approximately 84 years +/- 2 years) was shorter than the first (approximately 98 years +/- 
40 years) and second (approximately 327 years). 7) The population in general had a better 
understanding of the spread of disease. 8) Scientists and medical personnel had adopted 
better practices. 9) Drastic measures were taken to stop spreading. These differences are 
indeed relative, but do not necessarily suggest that "penicillin stopped the plague." In fact, 
these differences suggest that development of a drug that the organism thought to be 
responsible for each plague, Yersinia pestis, is susceptible to, was not the "cure all end all" 
for the disease. Nor will current antibiotics be the cure all for current and emerging 
diseases. Some of these differences suggest that without penicillin, the third pandemic 
could have been worse, or longer, or more deadly. For example, few people died despite 
the fact that more people were likely exposed and the pandemic ended sooner than the 
others. Figure 1 shows a graph of total reported infectious diseases of bacterial nature in 
the United States beginning in 1944 with the first available Morbidity and Mortality 
Weekly Report Summary (MMWR, 1994-2011). 
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In contrast however, some of these differences suggest that increased knowledge aided in 
the control of infection. Consider when comparing these pandemics, the trends within each 
pandemic. For example, during the second pandemic, there was little understanding about 
how to control infection; consequently we see a prolonged pandemic. During the third 
pandemic, we assume greater knowledge about infection control, we see shorter pandemics. 
After adding another variable, these seemingly related correlations lose strength. Consider 
also during the third pandemic, that the largest number of fatalities occurred during the first 
half of the pandemic, a time which perhaps surprisingly does not correlate to the availability 
of penicillin. The conclusion that should be drawn from these correlations is that the plague 
from the third pandemic likely differed enough that even without penicillin or increased 
knowledge of infection, the determents of the "Black Death" would not have been repeated. 
One then has to decide if the fact that our "miracle" drug may not have saved us should 
bring comfort as we face the emergence of other new "plagues" with no drugs to combat 
them, or whether the fact that the development of penicillin, if not solely responsible for 
stopping the plague, suggests that the development of new drugs may also not solve the 
"superbug" attack. As decision is considered, contemplate the following: It is most likely that 
genetic differences between the plague of the third pandemic and that of the second is 
responsible for the difference in outcomes, a difference in this case that likely spared much 
of the world's population; it is also these differences in genetics that are converting our bugs 
into "superbugs", perhaps this time not in our favor. 
 
 
Fig. 1. Reported Bacterial Based Infectious Disease in the United States 1944-2009, 
population corrected. Data were compiled by the authors using The Center for Disease 
Control Morbidity and Mortality Weekly Reports 1944-2000. *Included diseases Cholera,  
E. coli O157:H7, Meningococcal disease, Pertussis, Plague, Salmonellosis, Streptococcal disease 
(invasive, Group A), Streptococcus pneumoniae (drug resistant, invasive disease), Syphilis, 
Tuberculosis, Typhoid fever.  
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1.2 Emergence of the "superbug" 
The term "superbug" is readily used in the media and to some extent well understood by the 
public. The media has provided the public with a perceived understanding of the term, but 
unfortunately has not provided the same understanding of the implications of such 
"superbugs". Many of the references which are readily viewable on the internet are 
magazine articles that provide only bits of information with questionable accuracy. In 
general, the public thinks of a "superbug" as a uniquely contagious, potentially fatal 
infection that is not treatable with current medicines. Although the most important 
consideration is really the "superbug's" resistance to current antibiotics, the most prevalent 
issues to the public seem to be the endless number of dangerous nouns that can be preceded 
with the term "super." The concern over the development of the next pandemic of a "super-
contagious" or "super-fatal" infection fuels the fear of the public. Although today's 
"superbugs" are certainly contagious, they are not necessarily any more contagious than 
today's "non-superbugs." Likewise, they are not necessarily more inherently fatal than "non-
superbugs." Chances of fatality are higher because of the difficulty in treating and killing the 
bacteria.  
Another public misconception comes from the perceived rarity of these "superbugs." Even 
with the media announcing that hospital bugs have moved out of the hospital and into the 
community, in general it seems that the public still views their presence as rare and is 
shocked and frightened by reports of infections near their community. People in general 
find it disheartening to know that MRSA (methicillin resistant Staphylococcus aureus) is 
commonly found in many gyms for example. Studies demonstrate that the presence of 
"superbugs" such as MRSA is growing, so are the numbers of cases of infections growing as 
well? If it is everywhere, why don't we all have it? The key here is the same thing that leads 
to a difference in plague outcomes between the second and third pandemics: genetic 
differences. In lay terms, some bugs (note the intentional absence of "super") are more 
infectious than others, some people are more likely to get an infection than others, some 
infections are easier to treat than others, and some bugs are more susceptible to antibiotics 
than others. Considering all these differences, the only reliable way to define a "superbug" is 
scientifically, based on evidence.  
Ironically, the scientific definition of "superbug" doesn't have to differ much from the media 
definition, so long as the implications of the "superbugs" are understood clearly. Based on 
science, the term "superbug" refers to a bacterial organism which either is inherently or has 
developed resistance to at least one current antibiotic that would have typically been used to 
treat said bacteria. For example, the most well known type of hospital infection is staph, 
which when used to describe a post-operative infection is usually Staphylococcus aureus. 
Typical Staphylococcus aureus infections are treated with the penicillin class of antibiotics, 
such as nafcillin, oxacillin, dicloxacillin and methicillin. The more these infections were 
treated with these antibiotics, the better Staphylococcus aureus became at resisting the 
treatment. MRSA, stands for methicillin resistant Staphylococcus aureus and is perhaps the 
most well known "superbug."  
It is important to differentiate that technically viruses cannot be considered "superbugs". 
The term "bug" is reserved for bacterial organisms, however, it is very common to find the 
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phrase "superbug" applied to both bacteria and viruses in the media, and occasionally even 
in the scientific arena. The fact that these terms have both been included stems from the fact 
that both have the ability to mutate and both are infectious. Many viral infections develop 
accompanying bacterial infections as well, further complicating the differentiation. 
Comparison of infection trends makes it difficult to strictly separate the two as well because 
many viral related illnesses result in death from the subsequent development of bacterial 
infections. Many bacteria develop virulent strains, a term which is used to describe the 
degree of infectious nature, not indicating that the bacteria are a virus.  
1.3 Current and emerging threats 
The list of current "superbugs" is undefined. New strains of bacteria showing drug 
resistance are rapidly being identified. In 2006, the Antimicrobial Availability Task Force 
(AATF) of the Infectious Disease Society of America generated a list of drug resistant 
pathogens that was published in Clinical Infectious Disease (Talbot et al., 2006). Six pathogens 
were identified as "high-priority" for concern including: Acinetobacter baumannii, Aspergillus 
species, extended spectrum β-lactamase (ESBL)-producing Entrerbacteriaceae, vancomycin-
resistant Enterococcus faecium, Pseudomonas aeruginosa, and methicillin-resistant 
Staphylococcus aureus (MRSA). The AATF selected this list of bacterial and fungal pathogens 
based on the following characteristics: current clinical and/or public health concern in the 
United States (based on high infection incidence and substantial morbidity), infection with 
high attributable mortality rates, unique virulence or resistance factors rendering current 
therapeutics ineffective, and a lack of substantial or novel drug candidates (primarily those 
that had few candidates in the phase 2 or 3 trials).  
The gram negative bacterium Acinetobacter baumannii was included on the list because 
despite its historical lack of virulence, an increased number of severe infections have been 
identified. These infections have been identified as both hospital-acquired as well as 
community-acquired. A survey of infection in US intensive care units has indicated an 
increase of hospital acquired Acinetobacter pneumonia from 1.4% in 1975 to 6.9% in 2003. 
From 1975 to 2003 significant but smaller increases in bloodstream infection, surgical site 
infection, and urinary tract infection were also observed (Gaynes & Edwards, 2005). 
Increased incidence of Acinetobacter infections with drug-resistance have also been 
observed in military personnel with war-related injuries and survivors of the 2004 
tsunami. 
The inclusion of Aspergillus species on the list due to the increasing nature of invasive 
infections observed in immunocomprimised individuals (Maschmeyer & Ruhnke, 2004). 
Infections from Aspergillus fungi have a 50-60% mortality rate (Boucher et al., 2004). 
Additionally, several current treatments for Aspergillus infections require improvement both 
in the realm of efficacy as well as patient tolerace and safety. The top three drugs of choice 
for treatment of aspergillosis only have an approximate success rate of 40% (Walsh et al., 
1999, 2002, 2004 as cited in Talbot et al., 2006). These include amphotericin B deoxycholate, 
which is highly toxic unless administered in lipid formulation; caspsofungin, which only 
has FDA approval for second-line defense which is based on a study with a relatively small 
number of individuals; and voriconazole, which has documented common drug-drug 
interactions (Johnson & Perfect, 2003; Boucher et al., 2004). 
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Escherichia coli and Klebsiella species strains producing the extended spectrum β-lactamase 
(ESBL) were selected for the list due to common infection in the urinary, biliary or 
gastrointestinal tracts. There is also a common occurrence in trauma injury and surgical sites 
as well as a high incidence of hospital acquired pneumonia and postoperative meningitis 
(Decré et al., 2004; Kang et al., 2004; Meyer et al., 1993; Paterson et al., 2004a, 2004b; Quale et 
al., 2002; Weiner et al., 1999 as cited in Talbot et al., 2006). A 2001 survey for US intensive 
care units identified 11.2% and 16.2% occurrence of ESBL production in E. coil and Klebsiella 
species, respectively (Biedenbach et al., 2004; Streit et al., 2004). The most alarming 
observation is the large increase in the percentage of resistant pathogens relative to total 
reported cases. During a 2 year period, 56 out of 57 samples collected of Klebsiella oxytoca 
exhibited multi-drug resistance (Decré et al., 2004 as cited in Talbot et al., 2006). A survey of 
91 ESBL-producing Klebsiella species indicated resistance to gentamicin in 84% of the 
samples. Resistance to tri-methoprim-sulamethoxazole (70%), piperacillin-tazobactam 
(60%), and ciprofloxacin (51%) was also observed (Schwaoer et al., 2005).  
Limited treatment options and increased infections have led to the high-risk classification of 
vancomycin-resistant Enterococcus faecium. Recently high rates of resistance to glycopeptides 
treatment have been observed in the United States compounded with an increased incidence 
of Enterococcus faecium blood infection in patients, particularly infections related to catheter 
use (Murray, 2000; Wisplinghoff et al., 2004). High-risk patients, such as those that have 
received a liver transplant or have cancer, face a disturbingly high rate of infection near 70% 
(National Nosocomial Infections Surveillance [NNIS] System Report, 2004; Streit et al., 2004; 
Wisplinghoff et al., 2004). 
The severity of infections caused by Pseudomonas aeruginosa warrant the inclusion of this 
gram negative bacterium. Immunocompromised patients face potential fatal invasive 
infections (Maschmeyer & Braveny, 2000). Pseudomonas aeruginosa threatens a wide range of 
ages and includes lower respiratory and urinary tract infections. Infections occurring in 
patients with cystic fibrosis, often result in severe inflammation causing fatal damage to the 
lung tissue (Rajan & Saiman, 2002). Incidence of intensive care unit acquired pneumonia 
caused by Pseudomonas aeruginosa are increasing to approximately two times the rates 
observed in 1975. Similarly the infection rates of the urinary tract and surgical sites have 
doubled (NNIS System Report, 2004). Like other members of the "superbug" list, the rate at 
which Pseudomonas aeruginosa has developed drug resistance is distressing. From 1997 to 
2001 resistance to fluoroquinolones increased 37%, resistance to imipenem increased 32%, 
resistance to ceftazidime increased 22%, resistance to multiple-drugs increased 4% (NNIS 
System Report, 2003; Obritsch et al., 2004). 
The last pathogen included on the 2006 "superbug" list is perhaps the most well known, 
methicillin-resistant Staphylococcus aureus (MRSA). It is currently estimated that 
approximately 4 out of 1000 patients discharged from the hospital have a MRSA infection 
(Kuehnert et al., 2005). MRSA infections are more prominent in surgical or dialysis patients 
as well as premature infants. Hospital acquired MRSA infections were among the first 
identified and resulted in higher mortality rates. Recently, concern has risen over the 
number of cases occurring in the community, particularly in a crowed population. Currently 
vancomycin is the primary therapeutic used to combat MRSA infections, but strains 
showing vancomycin resistance are emerging (Fridkin et al., 2003). Hospitalizations due to 
MRSA infections, regardless of the cause of infection, have increased from 127,000 in 1999 to 
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280,000 in 2005 (Kallen et al., 2010; Klein et al., 2007; Klevens et al., 2007). Table 2 below 
summarizes the 2006 list of "superbug" threats as well as the reason for inclusion on the 
threat list. 
 
Pathogen Reason for list inclusion 
Acinetobacter 
baumannii 
Multi-drug resistant, hospital- and community-acquired, 
increasing incidence 
Aspergillus species Current drugs with low efficacy and/or side effects including 
drug-drug interactions, high mortality rate, increased invasive 
infections 
ESBL-producing 
Entrerbacteriaceae 
Increasing incidence, rapidly increasing drug-resistance, multi-
drug resistance 
vancomycin-
resistant 
Enterococcus 
faecium 
Increasing incidence of blood infections, high infection rates, 
increasing infection rates across patient care areas 
Pseudomonas 
aeruginosa 
Severity of infections, high mortality rate in high risk patients, 
increasing incidence, increasing resistance, multi-drug resistance 
methicillin-resistant 
Staphylococcus 
aureus (MRSA) 
Increasing resistance, hospital- and community-acquired, 
increasing incidence, rapid resistance development to current 
therapeutics 
Table 2. Summary of AATF List of Drug Resistant Pathogens requiring concern, 2006.  
Although not included on the 2006 AATF list, several additional organisms should be 
considered due to the emergence of similar characteristics. One such organism that should 
be added to a list of concern is Clostridium difficle. This organism has been identified as 
number one identifiable cause of diarrhea in HIV infected patients (Sanchez et al., 2005). 
Estimates suggest that drug-resistant and virulent form Clostridium difficle played a role in 
nearly 300,000 hospitalizations in 2005, a two-fold increase from 2000 before the virulent 
strain was prevalent. This study also suggested the fatality rate increased from 1.2% to 
2.2% from 2000 to 2004 (Zilberberg et al., 2008). Infection with Clostridium difficle results in 
production of two toxins, A and B. New evidence suggests that toxin B provides the 
virulent nature of Clostridium difficle (Lyras et al., 2009). Another organism which has 
rising concern over the development of multi-drug resistance is Neisseria gonorrhoeae, the 
bacteria that causes gonorrhea. As early as the 1970s, the United States has seen strains of 
Neisseria gonorrhoeae, resistant to penicillin and tetracycline. Many of the more recent 
strains have developed resistance to fluoroquinolines. Just reported in 2011, a multi-drug 
resistant strain known as H041 was identified in Japan (Ohnishi et al., 2011). Food-bourne 
diseases are also beginning to demonstrate resistance. Salmonella strains that are resistant 
to ciprofloxacin have recently emerged. An estimated 3.3 million cases of salmonella 
poisoning were reported in North American and Europe between 1999 and 2008, although 
these cases include both resistant and non-resistant strains (Le Hello et al., 2011; 
McConnell, 1999). Other diseases of particular concern that were included on the 
Notifiable Disease List in 2009 produced by the Center for Disease Control (CDC) include: 
Streptococcal species, Streptococcus pneumoniae, vancomycin-resistant Staphylococcus aureus 
(VRSA), Mycobacterium tuberculosis, Neisseria meningitidis, Bordetella pertussis, Vibrio cholera 
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(Christensen et al., 2009; Lynch et al., 2009; Morbidity and Mortality Weekly Report 
[MMWR], 2009; Phares et al., 2008; Robinson et al., 2001; Tanaka et al., 2003). Although in 
some of these cases antibiotic resistance is already observed, they are included primarily 
because of the availability of case reports with these diseases. Figure 2 represents a 
comparison of total reported cases of Streptococcal disease, invasive, group A to those 
that were drug resistant in the United States from 2002 to 2007. The percentage of cases 
that showed drug resistance are shown for each year. These data do not suggest a large 
increase in the number of reported cases but a trend of increasing resistance. Also, 
infections caused by these bacteria exhibit characteristics and trends similar to those 
bacterium that have been placed on the AATF list. 
 
 
Fig. 2. The total number of Streptococcal disease (invasive, group A) cases reported in the 
United States between 2002 and 2007 compared to the number of cases that demonstrated 
drug-resistance (shown as a percentage each year.) Data were compiled by the authors from 
the Center for Disease Control Morbidity and Mortality Weekly Reports, 2002-2007. 
2. How did bugs become "super?" 
2.1 Antibiotic misuse 
Perhaps the most commonly known cause of the development of antibiotic resistance is the 
so-called misuse of antibiotics. This phrase refers not only to the patient's adherence to 
antibiotic prescription instructions, but also to the doctors that prescribe antibiotics 
unnecessarily. Many times problems with over prescription of antibiotics comes from the 
patients demand. Perhaps doctors are concerned with patient satisfaction or wish to 
decrease the likelihood of a follow up visit for a viral illness which could result in a bacterial 
infection. It is possible that the patients have developed an expectation to leave the doctor's 
office with prescription in hand. Regardless of the reason, antibiotics administered for 
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unnecessary purposes, including non-bacterial infections and prophylaxis, encourage the 
development and the spread of antibiotic resistance. Considering one study that estimated 
over 90% of all infections are viral, yet over half the US patients are taking antibiotics for 
these viral infections (Science Daily, 2005).  
A study published in Science in 2010 utilized a genomic approach to examine single 
nucleotide polymorphisms using a high resolution second generation DNA sequencing 
platform. Researchers examined two samples: one was a global collection ranging from 1982 
to 2003 and the second was a collection from Thailand over a seven month period. Sample 
one represents a random population while the second samples are limited to a single 
transmission. The data suggests specific European samples from the global collection relate 
to those collected from the Thailand hospital. The complete set of data allowed phylogenic 
analysis and an estimation of time since the evolution of the resistance. The researchers 
observed that 28.9% of the homoplasies identified had direct links to current therapeutics, 
providing strong evidence that the misuse of antibiotics in today's medical practice is a 
major contributor to the development of resistance. Furthermore, this study has allowed an 
estimate of one single nucleotide polymorphism every six weeks, an essentially 
unimaginable rate in evolutionary time (Harris et al., 2010). 
The second part of this concern is patient adherence. This usually stems from the fact that 
antibiotic treatment, assuming it is a non-resistant bug, usually improves clinical symptoms 
within 1 to 3 days. Patients have difficulty continuing to take the prescription when their 
symptoms have been alleviated. They also have a tendency to "save" the rest of the 
prescription in case they need it again in the future. The contribution of this action to 
antibiotic resistance is simple: initial treatment kills most of the bacteria, particularly those 
susceptible to the antibiotic; those with some minor susceptibility to the antibiotic survive 
and thrive as the dosing is waned. Essentially this is an acceleration of "survival of the 
fittest." Bacteria that have been able to survive, reproduce and pass along whatever genetic 
variance they carry which provides resistance. 
Recent reports have warned the overuse of antibiotics as prophylaxis in the food industry, 
although there is some controversy over the actual contribution to food animal antibiotic 
administration to the growing problem of global "superbug" problems (Singer et al., 2003). It 
is proposed that unnecessary use of antibiotics in food animals will contribute to resistance 
in the same ways as over prescribing and lack of adherence in the human population. 
2.2 Common household "superbug" advancement 
Although antibiotic misuse is perhaps the most publicized cause of "superbug" 
development, several similar mechanisms advance the resistant strains as well. Antibacterial 
soap is one example in which a large sample of weaker bugs is being killed, allowing the 
tough survivors to expand their gene pool. Many antibacterial products contain the 
ingredient triclosan, which functions by inhibiting essential fatty acid synthesis. Surviving 
bacteria develop a resistance to triclosan and are therefore not affected by future triclosan 
based cleansing. Laboratory experiments demonstrate that E. coli variants which developed 
resistance to triclosan did so via a mutation in the fab1 gene. Fab1 encodes the enzyme enoyl 
reductase, an enzyme essential for fatty acid metabolism, a mechanism untouched by most 
of today's antibiotics (Levy, 2000). Further experiments suggest two hours (4-8 hours for 
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resistant strains) are required to kill 90% of susceptible E. coli when treated with soap 
containing 150 µg/ml triclosan (Levy, 2000).  
The thought of "superbug" advancement in your home can be disturbing, but understanding 
where bacteria and fungi are found, where they live, and what strains they are can help 
educate the public about cleanliness in the home. It is important to point out here that my 
mentioning cleanliness in a review on "superbugs," one might imagine that evidence 
suggests we need to use more antibacterial cleaners and clean more, however, this is not 
necessarily the case. Most likely what is required is a solid education about the spread of the 
organisms, most importantly how to wash your hands. In reality, what is really required is 
not a better cleaner or more cleaning, but longer cleaning. A recent article in Popular 
Mechanics examined places in your home where microorganisms are likely thriving and 
identified the top five: refrigerator (particularly the vegetable drawer), dishwasher, air 
around the trash can and the trash can itself, washing machine, and the shower head. 
Presented results indicated that 23.4% of the bacteria found in the refrigerator was Klebsiella 
pneumoniae; the potentially infectious bacteria Pseudomonas aeruginosa were found in the 
washing machine; bacteria samples collected from the trash and the air around the trash 
contained Staphylococcus aureus, approximately 33% of which were methicillin resistant; 
Exophiala fungi capable of infecting humans was found in the dishwasher; and 
Mycobacterium avium, a bacteria that is usually benign but can infect immunocompromized 
individuals, was found in the shower head (Grunbaum, web, 2011). The important point to 
take from both of these "household" examples is that any cleansing treatment (hands, body, 
and refrigerator) must be approached with sufficient cleanser and sufficient time to ensure 
that maximal bacteria or fungus has been extinguished.  
2.3 Resistant gene transfer 
Misuse of antibiotics and antibacterial products have forded bacteria the opportunity to 
evolve resistance via one or more mechanisms of DNA alteration. Generally speaking, the 
result of these DNA alterations is either a modification that allows the bacteria to modify 
the drug chemically, rapidly remove the drug from the cell or prevent drug entry into the 
cell, or prevents binding of the drug by modifying the drug's target site. Likewise, certain 
bacteria are inherently resistant to some antibiotics. For example, gram negative bacteria 
are resistant to a number of antibiotics that are typically effective for gram positive 
bacteria, such as vancomycin. This resistance comes from the outer cell membrane layer 
that surrounds gram negative bacteria but not gram positive bacteria (Ibezim, 2005). The 
most pressing concern, however, is the rate of spread of so called acquired resistance. 
Acquired resistance refers to the presence of DNA encoding resistance, either through 
mutations or so called horizontal gene transfer (which is the exchange of resistance genes 
among different bacterial species). Mutations are thought to occur about one in every 108 
to 109 bacteria (Todar, 2009). Once bacteria develop a mutation that allows it to survive in 
the presence of antibiotics, this trait is passed on via a process known as vertical gene 
transfer through the replication of DNA and growth of new cells. Of these two processes, 
it is horizontal gene transfer that contributes most considerably to the mass wave of 
resistant bacteria.  
Bacteria are equipped with a variety of mechanisms capable of gene exchange including 
conjugation, transduction, and transformation which are all methods of horizontal gene 
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transfer. Likewise, bacteria can undergo gene exchange by sequence specific mechanisms 
such as transposition. Conjugation refers the interaction between two bacterial cells through 
a sex pillus, which allows polymerase mediated duplication of plasmid DNA to be 
transferred or exchanged. Oftentimes, these plasmid molecules contain a gene which 
encodes resistance. The second method, transduction, also involves incorporation of new 
DNA. Transduction involves transfer of genetic material via a bacteriophage, which injects 
DNA with potential resistance genes included into a host cell. Infection stimulates the 
production of new phage molecules with both phage DNA and host cell DNA, which upon 
infection into another host cell will result in incorporation of the original host cell DNA 
(presumably containing a resistance gene) into the chromosome of the newly infected cell. 
Fragmented pieces of DNA from donor cells, which may confer resistance, are taken up by 
new cells via the process of transformation (Tortora, 2003).  
Likewise, bacteria can undergo gene exchange by sequence specific mechanisms such as 
transposition. Transposition occurs when a resistance gene is flanked with genes encoding 
enzymes known as transpoase. These enzymes, together with sequences of DNA known as 
insertion sequences, when expressed, facilitate the transfer and insertion of the resistance 
gene into host DNA. This mechanism is referred to as horizontal gene transfer because the 
gene sequence along with DNA encoding machinery for further transposition activity are 
incorporated in a cross-over like process between two strands of DNA (Tortora, 2003).  
Thus far, a variety of genes have been identified that confer resistance when expressed. One 
of the most widely publicized was the New Dehli Metallo-β-lactamase (NDM-1) 
(Kumarasamy et al., 2010). The NDM-1 gene encodes an enzyme known as carapenemase, 
which is a β-lactamase that acts specifically on carbanpenem antibiotics, a class which until 
recently reserved for infections demonstrating resistance to other antibiotics. Likewise the β-
lactamase activity affords organisms carrying this gene resistance to all β-lactam antibiotics, 
including cephalosporins, many glycopeptides, monobactams, and penicillins (Walsh, 2008). 
The gene is capable of horizontal gene transfer and has been observed in select strains of E. 
coli and Klebsiella pneumoniae (Yong et al., 2009).  
3. Current, emerging, and needed therapies 
3.1 Current therapies 
Many of the existing therapies for bacterial infections function via similar mechanisms of 
action. In general antibiotics inhibit one of three cellular mechanisms including: protein 
synthesis (aminoglycosides, macrolides, tetracyclines, and others including streptomycin, 
chloramphenicol, linezolid, quinupristin/dalfopristin); cell wall synthesis (carbapenems, 
cephalosporins, glycopeptides, and penicillins); or topoisomerase activity (quinolones) (Lexi 
Comp, Inc., 2011). There are a few select antibiotics that have a unique mechanism of action 
including: daptomycin, which binds to the cell membrane and causes rapid depolarization 
thus inhibiting synthesis of nucleic acids and proteins; trimethoprin-sulfamethoxazole, 
which interferes substantially with bacterial folic acid synthesis; and metronidazole, which 
results in breakdown of DNA helical structure (Lexi-Comp, Inc., 2011). Table 3 summarizes 
selected current antibiotics used for bacterial disease and infection, specifically those 
currently indicated for infections caused by organisms that have been added to the 
"superbug" list.  
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Generic     Common Uses 
Aminoglycosides 
Gentamicin Infections due to gram- organisms & gram+ Staphylococcus 
Kanamycin Infections caused by E. coli, E. aerogenes, K. pneumoniae, Acinetobacter spp 
Carbapenems 
Imipenem/ Cilastatin
Infections of LRT, UT, bone, skin; infections due to gram+ bacteria (S. 
aureus, Streptococcus spp), resistant gram- bacilli (including EBSL-
producing E. coli, Klebsiella spp, Enterobacter spp, P. aeruginosa) 
Meropenem Meningitis caused by S. pneumoniae, N. meningitidis; skin infections 
Cephalosporins 
Cefotaxime 
Infections of RT, skin, bone, UT due to gram(- bacilli (not Pseudomonas), 
gram+ cocci (not enterococcus), many penicillin-resistant pneumococci. 
Cefepime 
UTIs due to E. coli, K. pneumoniae; infections of skin due to methicillin-
susceptible staphylococci; pneumonia due to S. pneumoniae, K. 
pneumoniae, Enterobacter spp; Enterobacter spp 
Glycopeptides 
Vancomycin Infections caused by staphylococcal spp, streptococcal spp, C. difficile  
Lipopeptide 
Daptomycin 
Infections due to gram+ organisms; endocarditis caused by MSSA or 
MRSA  
Macrolides 
Azithromycin Infections of U/LRT, skin; CAP, infections due to S. aureus, S. pneumoniae 
Clarithromycin Infections due to S. pneumoniae, S. aureus, S. pyogenes,  
Penicillins 
Ampicillin 
Infections due to non-β-lactamase-producing organisms, streptococci, 
pneumococci, meningococci, some Salmonella, Enterobacter, Klebsiella 
Penicillin G 
Sepsis, pneumonia, endocarditis, meningitis; infections due to gram+ 
organisms (generally not S. aureus), some gram- organisms  
Quinolones 
Ciprofloxacin Infections of the UT, LRT, skin, bone infections; gonorrhea; HAP 
Levofloxacin CAP, MDRSP, HAP, UTI, skin infections  
Moxifloxacin CAP, MDRSP, bronchitis, skin infections, intra-abdominal infections 
Sulfonamides 
Trimethoprim-
Sulfamethoxazole 
UTIs due to E. coli, Klebsiella & Enterobacter spp, bronchitis due to S. 
pneumoniae 
Tetracyclines 
Doxycycline 
Infections caused by Chlamydia, Mycoplasma, N. gonorrhoeae, Clostridium, 
B. anthracis, uncommon gram- & + organisms; syphilis; CAP 
Others 
Chloramphenicol 
Infections due to organisms resistant to other antibiotics caused by N. 
meningitidis, Salmonella; vancomycin-resistant enterococci 
Linezolid 
HAP caused by S. aureus (including MRSA) or S. pneumoniae (including 
multidrug-resistant strains), skin infections, CAP caused by gram+ 
organisms, Vancomycin-resistant E. faecium (VRE) infections 
Table 3. Selected antibiotic therapeutics and selected common uses. Data were compiled with 
Lexi-Comp Online in August 2011. Spp=species; CAP=community acquired pneumonia; 
MDRSP = multidrug-resistant S. pneumoniae; U/LRT = upper/lower respiratory tract;  
UTI = urinary tract infection; HAP = hospital acquired pneumoniae (Lexi-Comp, Inc., 2011).  
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In regards to the specific organisms which have documented resistant strains, the following 
drugs demonstrate efficacy: The imipenem/cilastatin combination has been effective against 
resistant gram negative bacilli such as the ESBL-producing E.coli and Klebsilla species and the 
Enterobacter species and Psendomonas aeruginosa. Ceftoaxime has demonstrated efficacy against 
some penicillin-resistant pneumococci. Treatment of MRSA and MSSA has been successful 
with daptomycin. The primary quinolones used for drug resistant S. pneumoniae are 
levofloxacin and moxifloxacin. Chloramphenicol, although quite toxic, has demonstrated 
activity against many vancomycin-resistant enterococci. Perhaps the most notable is linezolid, 
which is a newer antibiotic designed to inhibit bacterial protein synthesis, albeit by binding the 
bacterial 23S ribosomal RNA of the 50S subunit and preventing formation of the 70S subunit. 
This antibiotic has been effective against vancomycin-resistant Enterococcus faecium (VRE), 
nosocomial pneumonia caused by both methicillin susceptible and methicillin resistant forms 
of Staphylococcus aureus as well as Streptococcus pneumoniae including those that are multidrug 
resistant. Also of worthy attention is the relatively few side effects documented for patients 
treated with linezolid (Lexi-Comp, Inc., 2011). Table 4 summarizes selected infections as well 
as recommended and alternative treatment combinations. 
 
Pathogen Recommended Adult Drug Therapy Alternative Drug Therapy 
Pseudomonas 
Aeruginosa 
Ceftazidime plus Aminoglycosides or 
Penicillins, Extended-Spectrum plus 
Aminoglycosides or Cefepime plus 
Aminoglycosides 
Imipenem and Cilastatin or 
Meropenem plus Aminoglycosides or 
Ciprofloxacinplus Penicillins, 
extended Spectrum or Aztreonam 
Aspergillus 
Species 
Voriconazole 
Amphotericin B (Lipid Complex), 
Echinocandins, Itraconazole, 
Posaconazole 
Sallmonella 
Species 
Cephalosporins, 3rd Generation 
Ampicillin, Sulfamethoxazole and 
Trimethoprim, Chloramphenicol, 
Ciprofloxacin 
Enterococcus 
Species 
Penicillin G plus (Gentamicin or 
Streptomycin) or Ampicillin plus 
(Gentamicin or Streptomycin); 
Vancomycin-resistant Enterococcus: 
Linezolid, Quinupristin and 
Dalfopristin, Doxycycline, 
Choramphenicol 
Vancomycin plus Gentamicin or 
Penicillin G Plus Streptomycin or 
Ampicillin plus Streptomycin 
Staphylococcus 
aureus, 
Methicillin-
Resistant 
Vancomycin 
Daptomycin, Doxycycline, linezolid, 
Quinupristin and Dalfopristin, 
Sulfamethoxazole and Trimethoprim 
Clostridium 
difficle 
Metronidazole vancomycin 
Neisseria 
gonorrhoeae 
Cefixime, Ceftriaxone 
Monotherapy: Cefotaxime, 
Spectinomycin 
Bordetella 
pertussis 
Erythromycin 
Azithromycin, Clarithromycin, 
Tetracycline, Sulfamethoxazole and 
Trimethoprim, Chloramphenicol 
Table 4. Summary of selected infectious organisms and the recommended and alternative 
treatments (Lexi-Comp, Inc., 2011). 
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3.2 Emerging therapies 
In the recent years there have been a few significant developments of new antibiotics. 
Ceftaroline, often referred to as a 5th generation cephalosporin, has shown activity against 
multidrug resistant gram positive bacteria (Bazan et al., 2009; Steed & Ryback, 2010).  
Ceftaroline fosamil is a prodrug form which is rapidly converted to the active form after 
administered (Bazan et al., 2009). Like other cephalosporins, it binds to penicillin binding 
proteins (PBP), but differs from other β-lactams in that it has a high affinity for PBP2a, 
which is unique to MRSA (Steed & Ryback, 2010). Ceftaroline has been successfully used for 
the treatment of skin and skin structure infections caused by methicillin resistant S. aureus, 
S. pyogenes, S. agalactiae, E. coli, K. oxytoca, and K. pneumoniae (Bazan et al., 2009; Product 
insert, 2010; Saravolatz et al., 2010a, 2011b; Snydman et al., 2010; Steed & Ryback, 2010). The 
most common side effects reported were diarrhea, nausea, constipation, vomiting, increased 
transaminases, hyperkalemia, rash, and phlebitis (Hester et al., 2011). 
Another recent addition to approved antibiotics is telavancin. Telavancin is a 
lipoglycopeptide derivative of vancomycin that inhibits bacterial cell wall synthesis 
(Saravolatz et al., 2009). When compared to vancomycin, talavancin has demonstrated 
effectiveness in treatment of skin and skin structure infections caused by methicillin 
resistant S. aureus, S. pyogenes, S. agalactiae, S. pneumoniae, and vancomycin resistant E. 
faecalis (Stryjewski et al., 2006a, 2006b, 2008c). The drug has also been explored for use in 
hospital acquired pneumonia (Rubinstein et al., 2011). The most common side effects 
reported included: nausea, vomiting, foamy urine, and disturbance in taste (Medical Letter, 
2010).  
A recent carapenem, doripenem, has demonstrated a broad spectrum of antimicrobial 
activity against gram positive and negative bacteria including P. aeruginosa (included some 
cabapenems resistant strains) (Jones et al., 2004; Lister, 2007; Mushtaq et al., 2004). 
Doripenem is indicated for complicated intra-abdominal and urinary tract infections due to 
enterococci, anaerobes, and P. aeruginosa as well as hospital acquired pneumonia resulting 
from Klebsiella, Enterobacter, Acinetobacter, and Serratia species or in some cases S. aureus 
(Medical Letter, 2007; Solomkin et al., 2003). Aside from allergic reactions, the most 
commonly reported side effects included: headache, nausea, diarrhea, rash, and phlebitis 
(Horiuchi et al., 2006). 
Retapamulin is a recently approaved topical antibiotic effective for treatment of impetigo 
due to S. pyogenes and methicillin-susceptible S. aureus (Rittenhouse et al., 2006). Activity 
against MRSA has been observed in vitro (Rittenhouse et al., 2006). This antibiotic is derived 
from fermentation of fungi and represents the first in a class of antibiotics known as 
pleuromutilins. Drugs from this class interfere with bacterial protein synthesis by acting on 
the 50S subunit of the ribosome (Yan et al., 2006). Reported side effects are minimal and 
included only site irritation (Parish et al., 2008; Parish et al., 2006). 
Lastly, consideration of some not yet approved but promising antibiotics is warranted. In 
early 2011, results of a phase 3 clinical trial for a new antibiotic called fidaxomicin were 
published (Louie et al., 2011). Fidaxomicin starts a new class of antibiotics referred to as 
macrocycles. The drug offers a narrow range of activity as it is designed specifically for C. 
difficile (Louie et al., 2011). The clinical studies reported that fidaxomicin treated patients had 
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fewer recurrent episodes of C. difficle infection than patients taking vancomycin (Louie et al., 
2011). Another potential antibiotic worth considering is referred to as kibdelomycin, which 
was selected based on screening against multiple engineered strains of S. aureus. Although 
the structure identified was unique, it was found to function as a type II topoisomerase 
inhibitor and has demonstrated activity primarily against gram positive bacteria. Although 
it functions as a topoisomerase inhibitor, it is unique in the fact that it specifically inhibits 
the ATPase activity of bacterial type II topoisomerases (Phillips et al., 2011). Another 
promising publication in Nature suggests that a new inhibitor (GSK299423) has 
demonstrated broad spectrum activity by inhibiting DNA gyrase. The promising detail 
about this inhibitor is that crystal structures have indicated that the inhibitor binds to a non-
catalytic site on the DNA gyrase, as compared to the binding site for most fluoroquinolones, 
thus representing a new class of antibiotics and making this a prime target for further 
development (Bax et al., 2010). 
3.3 Therapeutic concerns and the need for continued antibiotic development 
The concern over the current antibiotics available is that the majority function via one or two 
general mechanisms. Currently the carbapenems are "last line" therapy for many resistant 
bacteria; the emergence of the NDM-1 gene demonstrates not only an organism's ability to 
withstand treatment from the majority of available antibiotics, but also demonstrates the 
threat of effective transposition based spreading from the gene. Many "newer" antibiotics 
function via some slight variation of previous mechanisms, for example inhibiting protein 
synthesis by binding one of the ribosomal subunits at a different location or a with a 
different affinity. Bacteria are likely to rapidly develop resistance mechanisms for antibiotics 
that function so similarly. Currently there are very few approved antibiotics with novel 
mechanisms and the "drug development pipeline" does not include a substantial number of 
new designs. 
The emergence of the multidrug resistance element NDM-1 suggests the urgency for the 
development of drastically novel function antibiotics. The over publicized, and perhaps mis-
publicized, evolution of "superbugs" has forced both public and government attention to the 
uncertain nature of our microbial defense. The necessity of government support through 
funding is essential in order to develop drugs that are positioned to enter the "pipeline." 
Considering the time required for drug development, the risk of global spread of resistance 
is alarming. 
4. Conclusion 
4.1 Prevention of antibiotic resistance 
Data clearly demonstrate a rise in the number of resistant organisms as well as in increase in 
the number of multidrug resistant bacteria. Based on the relative mutation rate and gene 
transfer rates, there is indeed a global concern over a future inability to treat bacterial 
infection effectively and without toxic side effects. Today's medical treatments and surgical 
capabilities have advanced modern medicine just as the discovery and development of 
penicillin marked a turning point in therapeutics. Emerging resistant mechanisms and 
organisms place the world on a path not only similar to an era before penicillin, but also to 
an era where medical surgical procedures become impossible to the risk of infection. New 
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multidrug resistance elements, in particular, NDM-1, is concerning because of its potential 
to travel between species and produce "superbugs" at rates well beyond the limit of natural 
selection. History has demonstrated that organisms have been able to develop resistant 
mechanisms rapidly once introduced to new antibiotics, and in particular once introduced 
to a new class of antibiotics. Continued responsible use of antibiotics is currently the best 
way to attempt to slow down the development of resistant strains. Careful attention should 
be paid to when antibiotics are prescribed, but even more importantly which antibiotics are 
prescribed. It is extremely important to reserve new antibiotics for strains that have 
demonstrated resistance to other drugs. Infatuation with "hot" new drugs has the potential 
to accelerate the selection of resistant organisms and render the new drugs ineffective as 
well. Consideration for patient compliance is also important; ensuring that the full course of 
antibiotic is taken will produce maximal eradication of the bacteria, leaving no remaining 
cells to pass on their "secret" of survival. 
4.2 Spread the research and spread the word 
Financial cutbacks by large drug companies and governmental funding cuts have slowed 
the potential for development of novel antibiotics. Although the high risk - high payoff drug 
development programs are waning, smaller research groups and companies are in a 
position to collaborate and share promising results thereby forming a network of antibiotic 
development team members. In recent years, the pressure to "develop and sell" outweighed 
the pressure to "develop and share". Perhaps with the economic setbacks, the "develop and 
share" model will accelerate design of new drugs. The importance of sharing knowledge 
with colleagues is evident, but the necessity of correctly explaining our current state to the 
general public should be equally considered. A clear understanding of the investment, both 
time and financial, required to bring a drug to market needs to be highlighted so that 
everyone has the motivation to slow the spread of resistance and give the drug development 
industry an opportunity to excel. 
5. References 
The Choice of Antibacterial Drugs. (2001). Medical Letter on Drugs and Therapeutics, Vol. 43, 
No. 1111-2, pp. (69-78) ISBN 0025-732X 
Vibativ (Telavancin) for Skin and Skin Structure Infections. (2009). Journal of Drugs in 
Dermatology, Vol. 8, No. 12, pp. (1151-1151) ISBN 1545-9616 
Telavancin (Vibativ) for Gram-Positive Skin Infections. (2010). Medical Letter on Drugs and 
Therapeutics, Vol. 52, No. 1329, pp. (1-2) ISBN 0025-732X 
Apostol, M., et al. (2009). Trends in Perinatal Group B Streptococcal Disease-United States, 
2000-2006 (Reprinted from MMWR, Vol 58, Pg 109-112, 2009). Jama-Journal of the 
American Medical Association, Vol. 301, No. 12, pp. (1218-1220) ISBN 0098-7484 
Appelbaum, P.C., et al. (2009). Activity of Telavancin against Staphylococci and Enterococci 
Determined by MIC and Resistance Selection Studies. Antimicrobial Agents and 
Chemotherapy, Vol. 53, No. 10, pp. (4217-4224) ISBN 0066-4804 
Austin, A.S. (2003). A pest in the land: new world epidemics in a global perspective. University of 
New Mexico Press, ISBN 0826328717 Retrieved from: <http://openlibrary.org/ 
books/OL8167121M/A_Pest_in_the_Land> 
 
Superbugs: Current Trends and Emerging Therapies 289 
Balasubramamian, J. et al. (2011) Bad Bugs No Drugs – A Review on NDM-1. International 
Journal of Pharma and Bio Sciences, Vol. 2, No. 1, pp. (B-62- B67), ISSN 0975-6299, 
Retrieved from: <www.ijpbs.net> 
Bax, B.D., et al. (2010). Type IIA Topoisomerase Inhibition by a New Class of Antibacterial 
Agents. Nature, Vol. 466, No. 7309, pp. (935-U951) ISBN 0028-0836 
Bazan, J.A., et al. (2009). Newer β-Lactam Antibiotics: Doripenem, Ceftobiprole, Ceftaroline, 
and Cefepime. Infectious Disease Clinics of North America, Vol. 23, No. 4, pp. (983-+) 
ISBN 0891-5520 
Bellis, M. (n.d.) History of Penicillin, In: About.Com Inventors, August 12, 2011, Available 
from: < http://inventors.about.com/od/pstartinventions/a/Penicillin.htm> 
Biedenbach, D.J., et al. (2004). Occurrence and Antimicrobial Resistance Pattern 
Comparisons among Bloodstream Infection Isolates from the Sentry Antimicrobial 
Surveillance Program (1997-2002). Diagnostic Microbiology and Infectious Disease, Vol. 
50, No. 1, pp. (59-69) ISBN 0732-8893 
Boucher, H.W., et al. (2004). Newer Systemic Antifungal Agents - Pharmacokinetics, Safety 
and Efficacy. Drugs, Vol. 64, No. 18, pp. (1997-2020) ISBN 0012-6667 
Cardo, D., et al. (2004). National Nosocomial Infections Surveillance (NNIS) System Report, 
Data Summary from January 1992 through June 2004, Issued October 2004. 
American Journal of Infection Control, Vol. 32, No. 8, pp. (470-485) ISBN 0196-6553 
Chinedum, I.E. (2005). Microbial Resistance to Antibiotics. African Journal of Biotechnology, 
Vol. 4, No. 13, pp. (1606-1611) ISBN 1684-5315 
Christensen, K.L.Y., et al. (2009). Infectious Disease Hospitalizations in the United States. 
Clinical Infectious Diseases, Vol. 49, No. 7, (Oct), pp. (1025-1035) ISBN 1058-4838 
Daileader, P. (2007). The Late Middle Ages. The Teaching Co., Chantilly, VA 
Decre, D., et al. (2004). Outbreak of Multi-Resistant K. oxytoca Involving Strains with 
Extended-Spectrum β-Lactamases and Strains with Extended-Spectrum Activity of 
the Chromosomal β-Lactamase. Journal of Antimicrobial Chemotherapy, Vol. 54, No. 5, 
(Nov), pp. (881-888) ISBN 0305-7453 
Fridkin, S.K., et al. (2003). Epidemiological and Microbiological Characterization of 
Infections Caused by S. aureus with Reduced Susceptibility to Vancomycin, U.S, 
1997-2001. Clinical Infectious Diseases, Vol. 36, No. 4, pp. (429-439) ISBN 1058-4838 
Gaynes, R., et al. (2005). Overview of Nosocomial Infections Caused by Gram-Negative 
Bacilli. Clinical Infectious Diseases, Vol. 41, No. 6, pp. (848-854) ISBN 1058-4838 
Grunbaum, M. 5 Places in Your Home that are Breeding Superbugs. Popular Mechanics, 
Retrieved from < http://www.popularmechanics.com/science/health/5-places- 
in-your-home-that-are-breeding-superbugs> 
Hays, J.N. (2005). Epidemics and pandemics: their impacts on human history. ABC-CLIO, Inc. 
ISBN 9781851096589. Retrieved from: <http://0- ebooks.ohiolink.edu.polar.onu. 
edu/xtf-ebc/view?docId=tei/abc/DISWHE/DISWHE.xml&query=&brand 
=default> 
Hecker, J.F.C. (1835). The epidemics of the middle ages. Sherwood, Gilbert and Piper. Retrieved 
from: <http://books.google.com/books?id=lDynaxN2Q-cC>  
Horiuchi, M., et al. (2006). Absence of Convulsive Liability of Doripenem, a New 
Carbapenem Antibiotic, in Comparison with β-Lactam Antibiotics. Toxicology, Vol. 
222, No. 1-2, (May 1), pp. (114-124) ISBN 0300-483X 
 
Antimicrobial Agents 290 
Johnson, M.D. & Perfect, J.R. (2003). Caspofungin: First Approved Agent in a New Class of 
Antifungals. Expert Opinion on Pharmacotherapy, Vol. 4, No. 5, (May), pp. (807-823) 
ISBN 1465-6566 
Jones, R.N., et al. (2004). Activities of Doripenem (S-4661) against Drug-Resistant Clinical 
Pathogens. Antimicrobial Agents and Chemotherapy, Vol. 48, No. 8, (Aug), pp. (3136- 
3140) ISBN 0066-4804 
Kallen, A.J., et al. (2010). Health Care-Associated Invasive MRSA Infections, 2005-2008. 
Journal of the American Medical Association, Vol. 304, No. 6, (Aug 11), pp. (641-648) 
ISBN 0098-7484 
Kang, C.I., et al. (2004). Bloodstream Infections Due to Extended-Spectrum β-Lactamase- 
Producing E. coli and K. pneumoniae: Risk Factors for Mortality and Treatment 
Outcome, with Special Emphasis on Antimicrobial Therapy. Antimicrobial Agents 
and Chemotherapy, Vol. 48, No. 12, pp. (4574-4581) ISBN 0066-4804 
Klevens, R.M., et al. (2007). Invasive Methicillin-Resistant S. aureus Infections in the U.S. 
Journal of the American Medical Association, Vol. 298, No. 15, (Oct 17), pp. (1763-1771) 
ISBN 0098-7484 
Kuehnert, M.J., et al. (2005). Methicillin-Resistant – S. aureus Hospitalizations, U.S. Emerging 
Infectious Diseases, Vol. 11, No. 6, (Jun), pp. (868-872) ISBN 1080-6040 
Lexi-Comp, Inc. (2011). August 22, 2011, Available from: <http://online.lexi.com/crlsq/ 
servlet/crlonline> 
Lister, P.D. (2007). Carbapenems in the USA: Focus on Doripenem. Expert Review of Anti- 
Infective Therapy, Vol. 5, No. 5, (Oct), pp. (793-809) ISBN 1478-7210 
Louie, T.J., et al. (2011). Fidaxomicin versus Vancomycin for C. difficile Infection. New 
England Journal of Medicine, Vol. 364, No. 5, pp. (422-431) ISBN 1533-4406  
Lynch, M.F., et al. (2009). Typhoid Fever in the U.S., 1999-2006. Journal of the American 
Medical Association, Vol. 302, No. 8, pp. (859-865) ISBN 0098-7484 
Maschmeyer, G. & Braveny, I. (2000). Review of the Incidence and Prognosis of P. aeruginosa 
Infections in Cancer Patients in the 1990s. European Journal of Clinical Microbiology & 
Infectious Diseases, Vol. 19, No. 12, pp. (915-925) ISBN 0934-9723 
Maschmeyer, G. & Ruhnke, M. (2004). Update on Antifungal Treatment of Invasive Candida 
and Aspergillus Infections. Mycoses, Vol. 47, No. 7, pp. (263-276) ISBN 0933-7407 
McConnell, H. (1999). Antibiotics and Superbugs. Futurist, Vol. 33, No. 2, (Feb), pp. (9-9) 
ISBN 0016-3317 
Meyer, K.S., et al. (1993). Nosocomial Outbreak of Klebsiella Infection Resistant to Late- 
Generation Cephalosporins. Annals of Internal Medicine, Vol. 119, No. 5, (Sep 1), pp. 
(353-358) ISBN 0003-4819 
Murray, B.E. (2000). Drug Therapy: Vancomycin-Resistant Enterococcal Infections. New 
England Journal of Medicine, Vol. 342, No. 10, (Mar 9), pp. (710-721) ISBN 0028-4793 
Mushtaq, S., et al. (2004). Doripenem versus P. aeruginosa in Vitro: Activity against 
Characterized Isolates, Mutants, and Transconjugants and Resistance Selection 
Potential. Antimicrobial Agents and Chemotherapy, Vol. 48, No. 8, (Aug), pp. (3086- 
3092) ISBN 0066-4804 
Obritsch, M.D., et al. (2004). National Surveillance of Antimicrobial Resistance in P. 
aeruginosa Isolates Obtained from Intensive Care Unit Patients from 1993 to 2002. 
Antimicrobial Agents and Chemotherapy, Vol. 48, No. 12, pp.(4606-4610) ISBN 0066- 
4804 
 
Superbugs: Current Trends and Emerging Therapies 291 
Ohnishi, M., et al. (2011). Is N. gonorrhoeae Initiating a Future Era of Untreatable Gonorrhea?: 
Detailed Characterization of the First Strain with High-Level Resistance to 
Ceftriaxone. Antimicrobial Agents and Chemotherapy, Vol. 55, No. 7, (Jul), pp. (3538-
3545) ISBN 0066-4804 
Parish, L.C., et al. (2006). Topical Retapamulin Ointment (1%, Wt/Wt) Twice Daily for 5 
Days versus Oral Cephalexin Twice Daily for 10 Days in the Treatment of 
Secondarily Infected Dermatitis: Results of a Randomized Controlled Trial. Journal 
of the American Academy of Dermatology, Vol. 55, No. 6, (Dec), pp. (1003-1013) ISBN 
0190-9622 
Parish, L.C. & Parish, J.L. (2008). Retapamulin: A New Topical Antibiotic for the Treatment 
of Uncomplicated Skin Infections. Drugs of Today, Vol. 44, No. 2, (Feb), pp. (91-102) 
ISBN 1699-3993 
Paterson, D.L., et al. (2004). Antibiotic Therapy for K. pneumoniae Bacteremia: Implications of 
Production of Extended-Spectrum β-Lactamases. Clinical Infectious Diseases, Vol. 39, 
No. 1, (Jul 1), pp. (31-37) ISBN 1058-4838 
Phares, C.R., et al. (2008). Epidemiology of Invasive Group B Streptococcal Disease in the 
United States, 1999-2005. Journal of the American Medical Association, Vol. 299, No. 17, 
(May 7), pp. (2056-2065) ISBN 0098-7484 
Phillips, J.W., et al. (2011). Discovery of Kibdelomycin, a Potent New Class of Bacterial Type 
II Topoisomerase Inhibitor by Chemical-Genetic Profiling in S. aureus. Chemistry & 
Biology, Vol. 18, No. 8, (Aug 26), pp. (955-965) ISBN 1879-1301  
Product Information for Tefarlo. (2010). Forest. St. Louis, MO 63042.  
Pryor, E.G. (1975). The Great Plague of Hong Kong. Journal of the Hong Kong Branch of the 
Royal Asiatic Society Vol. 15, pp. (61-70), ISSN 1991-7295 
Quale, J.M., et al. (2002). Molecular Epidemiology of a Citywide Outbreak of Extended- 
Spectrum β-Lactamase-Producing K. pneumoniae Infection. Clinical Infectious 
Diseases, Vol. 35, No. 7, (Oct 1), pp. (834-841) ISBN 1058-4838 
Rittenhouse, S., et al. (2006). Selection of Retapamulin, a Novel Pleuromutilin for Topical 
Use. Antimicrobial Agents and Chemotherapy, Vol. 50, No. 11, (Nov), pp. (3882-3885) 
ISBN 0066-4804 
Robinson, K.A., et al. (2001). Epidemiology of Invasive S. pneumoniae Infections in the U.S., 
1995-1998 - Opportunities for Prevention in the Conjugate Vaccine Era. Journal of the 
American Medical Association, Vol. 285, No. 13, pp. (1729-1735) ISBN 0098-7484 
Rosen, W. (2007). Justinian's flea: plague, empire, and the birth of Europe. Penguin. ISBN 
9780670038558. Retrieved from: <http://books.google.com/books?id=2oA2L 
biv4xAC>  
Rubinstein, E., et al. (2011). Telavancin versus Vancomycin for Hospital acquired 
Pneumonia Due to Gram-Positive Pathogens. Clinical Infectious Diseases, Vol. 52, 
No. 1, (Jan 1), pp. (31-40) ISBN 1058-4838 
Sanchez, T.H., et al. (2005). Bacterial Diarrhea in Persons with HIV Infection, United States, 
1992-2002. Clinical Infectious Diseases, Vol. 41, No. 11, (Dec 1), pp. (1621-1627) ISBN 
1058-4838 
Saravolatz, L., et al. (2010). In Vitro Activity of Ceftaroline against Community-Associated 
Methicillin-Resistant, Vancomycin-Intermediate, Vancomycin-Resistant, and 
Daptomycin-Nonsusceptible S. aureus Isolates. Antimicrobial Agents and 
Chemotherapy, Vol. 54, No. 7, (Jul), pp. (3027-3030) ISBN 0066-4804 
 
Antimicrobial Agents 292 
Saravolatz, L.D., et al. (2009). Telavancin: A Novel Lipoglycopeptide. Clinical Infectious 
Diseases, Vol. 49, No. 12, (Dec 15), pp. (1908-1914) ISBN 1058-4838 
Saravolatz, L.D., et al. (2011). Ceftaroline: A Novel Cephalosporin with Activity against 
Methicillin-Resistant S. aureus. Clinical Infectious Diseases, Vol. 52, No. 9, (May 1), 
pp. (1156-1163) ISBN 1058-4838 
Schwaoer, M.J., et al. (2005). High Levels of Antimicrobial Coresistance among Extended- 
Spectrum-β-Lactamase-Producing Enterobacteriaceae. Antimicrobial Agents and 
Chemotherapy, Vol. 49, No. 5, (May), pp. (2137-2139) ISBN 0066-4804 
Snydman, D.R., et al. (2011). In Vitro Activity of Ceftaroline against a Broad Spectrum of 
Recent Clinical Anaerobic Isolates. Antimicrobial Agents and Chemotherapy, Vol. 55, 
No. 1, (Jan), pp. (421-425) ISBN 0066-4804 
Solomkin, J.S., et al. (2003). Guidelines for the Selection of Anti-Infective Agents for 
Complicated Intra-Abdominal Infections. Clinical Infectious Diseases, Vol. 37, No. 8, 
(Oct 15), pp. (997-1005) ISBN 1058-4838 
Solomon, S., et al. (2003). National Nosocomial Infections Surveillance (NNIS) System 
Report, Data Summary from January 1992 through June 2003, Issued August 2003. 
American Journal of Infection Control, Vol. 31, No. 8, (Dec), pp. (481-498) ISBN 0196- 
6553 
Steed, M.E. & Rybak, M.J. (2010). Ceftaroline: A New Cephalosporin with Activity against 
Resistant Gram-Positive Pathogens. Pharmacotherapy, Vol. 30, No. 4, (Apr), pp. (375- 
389) ISBN 0277-0008 
Streit, J.M., et al. (2004). Assessment of Pathogen Occurrences and Resistance Profiles among 
Infected Patients in the Intensive Care Unit: Report from the Sentry Antimicrobial 
Surveillance Program (North America, 2001). International Journal of Antimicrobial 
Agents, Vol. 24, No. 2, (Aug), pp. (111-118) ISBN 0924-8579 
Stryjewski, M.E., et al. (2006). Telavancin versus Standard Therapy for Treatment of 
Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: 
Fast 2 Study. Antimicrobial Agents and Chemotherapy, Vol. 50, No. 3, (Mar), pp. (862- 
867) ISBN 0066-4804 
Stryjewski, M.E., et al. (2008). Telavancin vs. Vancomycin for the Treatment of Complicated 
Skin and Skin-Structure Infections Caused by Gram-Positive Organisms. Clinical 
Infectious Diseases, Vol. 46, No. 11, pp. (1683-1693) ISBN 1058-4838 
Stryjewski, M.E., et al. (2005). Telavancin vs. Standard Therapy for Treatment of 
Complicated Skin and Soft-Tissue Infections Due to Gram-Positive Bacteria. Clinical 
Infectious Diseases, Vol. 40, No. 11, (Jun 1), pp. (1601-1607) ISBN 1058-4838 
Study Explores Antibiotic Misuse. (2005). Science Daily, August 27, 2011, Available from:  
 < http://www.sciencedaily.com /releases/2005/01/050111162856.htm> 
Summary of Notifiable Diseases, United States, 2009 (2011) MMWR: Morbidity and Mortality 
Weekly Report, Vol. 58, No. 53, (May 2011), pp. (996-998), Retrieved from: 
<http://www.cdc.gov/mmwr> 
Summary of Notifiable Diseases, United States, 2008 (2010) MMWR: Morbidity and Mortality 
Weekly Report, Vol. 57, No. 54, (June 2010), pp. (1-94), Retrieved from: 
<http://www.cdc.gov/mmwr> 
Summary of Notifiable Diseases, United States, 2007 (2009) MMWR: Morbidity and Mortality 
Weekly Report, Vol. 56, No. 53, (July 2009), pp. (1-94), Retrieved from: 
<http://www.cdc.gov/mmwr> 
 
Superbugs: Current Trends and Emerging Therapies 293 
Summary of Notifiable Diseases, United States, 2006 (2008) MMWR: Morbidity and Mortality 
Weekly Report, Vol. 55, No. 53, (March 2008), pp. (1-94), Retrieved from: 
<http://www.cdc.gov/mmwr> 
Summary of Notifiable Diseases, United States, 2005 (2007) MMWR: Morbidity and Mortality 
Weekly Report, Vol. 54, No. 53, (March 2007), pp. (2-92), Retrieved from: 
<http://www.cdc.gov/mmwr> 
Summary of Notifiable Diseases, United States, 2004 (2006) MMWR: Morbidity and Mortality 
Weekly Report, Vol. 53, No. 53, (June 2006), pp. (1-79), Retrieved from: 
<http://www.cdc.gov/mmwr> 
Summary of Notifiable Diseases, United States, 2003 (2005) MMWR: Morbidity and Mortality 
Weekly Report, Vol. 52, No. 54, (April 2005), pp. (1-85), Retrieved from: 
<http://www.cdc.gov/mmwr> 
Summary of Notifiable Diseases, United States, 2002 (2004) MMWR: Morbidity and Mortality 
Weekly Report, Vol. 51, No. 53, (April 2004), pp. (1-84), Retrieved from: 
<http://www.cdc.gov/mmwr> 
Summary of Notifiable Diseases, United States, 2001 (2003) MMWR: Morbidity and Mortality 
Weekly Report, Vol. 50, No. 53, (May 2003), pp. (1-108), Retrieved from: 
<http://www.cdc.gov/mmwr> 
Summary of Notifiable Diseases, United States, 2000 (2002) MMWR: Morbidity and Mortality 
Weekly Report, Vol. 49, No. 53, (June 2002), pp. (1-102), Retrieved from: 
<http://www.cdc.gov/mmwr> 
Summary of Notifiable Diseases, United States, 1999 (2001) MMWR: Morbidity and Mortality 
Weekly Report, Vol. 48, No. 53, (April 2001), pp. (1-104), Retrieved from: 
<http://www.cdc.gov/mmwr> 
Summary of Notifiable Diseases, United States, 1998 (1999) MMWR: Morbidity and Mortality 
Weekly Report, Vol. 47, No. 53, (December 1999), pp. (1-93), Retrieved from: 
<http://www.cdc.gov/mmwr> 
Summary of Notifiable Diseases, United States, 1997 (1998) MMWR: Morbidity and Mortality 
Weekly Report, Vol. 46, No. 54, (November 1998), pp. (1-87), Retrieved from: 
<http://www.cdc.gov/mmwr> 
Summary of Notifiable Diseases, United States, 1996 (1997) MMWR: Morbidity and Mortality 
Weekly Report, Vol. 45, No. 53, (October 1997), pp. (1-87), Retrieved from: 
<http://www.cdc.gov/mmwr> 
Summary of Notifiable Diseases, United States, 1995 (1996) MMWR: Morbidity and Mortality 
Weekly Report, Vol. 44, No. 53, (October 1996), pp. (1-87), Retrieved from: 
<http://www.cdc.gov/mmwr> 
Summary of Notifiable Diseases, United States, 1994 (1995) MMWR: Morbidity and Mortality 
Weekly Report, Vol. 43, No. 53, (October 1995), pp. (1-74), Retrieved from: 
<http://www.cdc.gov/mmwr> 
Summary of Notifiable Diseases, United States, 1993 (1994) MMWR: Morbidity and Mortality 
Weekly Report, Vol. 42, No. 53, (October 1994), pp. (1-73), Retrieved from: 
<http://www.cdc.gov/mmwr> 
Talbot, G.H., et al. (2006). Bad Bugs Need Drugs: An Update on the Development Pipeline 
from the Antimicrobial Availability Task Force of the Infectious Diseases Society of 
America (Vol 42, Pg 657, 2006). Clinical Infectious Diseases, Vol. 42, No. 7, (Apr 1), 
pp. (1065-1065) ISBN 1058-4838 
 
Antimicrobial Agents 294 
Tanaka, M., et al. (2003). Trends in Pertussis among Infants in the U.S., 1980-1999. Journal of 
the American Medical Association, Vol. 290, No. 22, pp. (2968-2975) ISBN 0098-7484 
Todar, K. (2009). The Microbial World, University of Wisconsin, Madison, Retrieved from:  
 <http://textbookofbacteriology.net/themicrobialworld/bactresanti.html> 
Tortora, G.J. (Ed.) (2003). Microbiology: an introduction, Benjamin Cummings, IBSN 
0805376143, Menlo Park, Ca.  
Wade, N. (2010). Europe's Plagues Came from China, Study Finds, In: The New York Times, 
August 18, 2011, Available From: <http://www.nytimes.com/2010/11/01 
/health/01plague.html> 
Walsh, T.J., et al. (1999). Liposomal Amphotericin B for Empirical Therapy in Patients with 
Persistent Fever and Neutropenia. New England Journal of Medicine, Vol. 340, No. 10, 
(Mar 11), pp. (764-771) ISBN 0028-4793 
Walsh, T.J., et al. (2002). Voriconazole Compared with Liposomal Amphotericin B for 
Empirical Antifungal Therapy in Patients with Neutropenia and Persistent Fever. 
New England Journal of Medicine, Vol. 346, No. 4, pp. (225-234) ISBN 0028-4793 
Walsh, T.J., et al. (2004). Caspofungin vs. Liposomal Amphotericin B for Empirical 
Antifungal Therapy in Patients with Persistent Fever and Neutropenia. New 
England Journal of Medicine, Vol. 351, No. 14, pp. (1391-1402) ISBN 0028-4793 
Walsh, T.R. (2008). Clinically Significant Carbapenemases: An Update. Current Opinion in 
Infectious Diseases, Vol. 21, No. 4, (Aug), pp. (367-371) ISBN 0951-7375 
Walsh, T.R., et al. (2010). Emergence of a New Antibiotic Resistance Mechanism in India, 
Pakistan, and the UK: A Molecular, Biological, and Epidemiological Study. Lancet 
Infectious Diseases, Vol. 10, No. 9, (Sep), pp. (597-602) ISBN 1473-3099 
Wiener, J., et al. (1999). Multiple Antibiotic-Resistant Klebsiella and E. Coli in Nursing 
Homes. Journal of the American Medical Association, Vol. 281, No. 6, (Feb 10), pp. 
(517-523) ISBN 0098-7484 
Williams, B. (1997). Infectious Diseases in History: a guide to causes and effects. In: urbanrim.org. 
uk August 12, 2011, Available from: <http://urbanrim.org.uk/diseases.htm# 
Plague> 
Wisplinghoff, H., et al. (2004). Nosocomial Bloodstream Infections in US Hospitals: Analysis 
of 24,179 Cases from a Prospective Nationwide Surveillance Study. Clinical 
Infectious Diseases, Vol. 39, No. 7, (Oct 1), pp. (1093-1093) ISBN 1058-4838 
Yan, K., et al. (2006). Biochemical Characterization of the Interactions of the Novel 
Pleuromutilin Derivative Retapamulin with Bacterial Ribosomes. Antimicrobial 
Agents and Chemotherapy, Vol. 50, No. 11, (Nov), pp. (3875-3881) ISBN 0066-4804 
Zilberberg, M.D., et al. (2008). Increase in C. difficile-Related Hospitalizations among Infants 
in the US, 2000-2005. Pediatric Infectious Disease Journal, Vol. 27, No. 12, (Dec), pp. 
(1111-1113) ISBN 0891-3668 
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
